Oncology Today with Dr Neil Love

Епизоде

• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 8 16.09.2026 25мин

  Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 7 16.09.2026 36мин

  Featuring perspectives from Dr Alexandra Drakaki, including the following topics:Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)CME information and select publications
• 
  Breast Cancer — Reviewing Key Presentations from the 2026 ASCO Annual Meeting 15.09.2026 1ч 29мин

  Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:Introduction (0:00)Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)HER2-Positive Breast Cancer — Dr Bardia (42:46)Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)CME information and select publications
• 
  Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 14.09.2026 26мин

  Featuring perspectives from Dr Rachel N Grisham, including the following topics:Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)CME information and select publications
• 
  Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1 13.09.2026 28мин

  Featuring perspectives from Dr Rachel N Grisham, including the following topics:Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00)A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11)Current and future role of avutometinib with defactinib for LGSOC (19:23)A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37)CME information and select publications
• 
  Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus 11.09.2026 59мин

  Featuring an interview with Prof Andreas Hochhaus, including the following topics:Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)Potential mechanisms of adverse events documented with TKIs (10:23)Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)Comparative efficacy of asciminib and other agents used to treat CML (40:01)Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)Practical care strategies for CML patients; future developments (52:32)CME information and select publications
• 
  Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer 11.09.2026 20мин

  Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics:Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00)Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03)CME information and select publications
• 
  Non-Small Cell Lung Cancer — Targeting KRAS G12C 10.09.2026 57мин

  Featuring perspectives from Prof Solange Peters and Dr Joshua K Sabari, including the following topics:Introduction (0:00)Best Option for Your Patient (1:28)Biological Considerations (6:26)KRAS G12C Inhibitors (11:33)Second-Line Treatment (13:02)Current Clinical Trials in the First-Line Metastatic Setting (32:18)Current Clinical Trials in the Localized Setting (49:52)Current Clinical Trials with New Treatment Combinations and Agents (53:51)CME information and select publications
• 
  Prostate Cancer — The Optimal Use of Hormonal Therapy 08.09.2026 59мин

  Featuring perspectives from Dr William K Oh and Dr Mary-Ellen Taplin, including the following topics:Introduction: Another Perspective on the Treatment of Localized Prostate Cancer (0:00)Nonmetastatic Disease (10:32)Metastatic Androgen Pathway Modulation-Naïve and Androgen Pathway Modulation-Sensitive Disease (41:50)CME information and select publications
• 
  Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4 07.09.2026 30мин

  Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)Case: A man in his late 60s with bulky CLL diagnosed abroad receives zanubrutinib monotherapy (12:48)Case: A man in his late 40s with IGHV-mutated, del(13q) CLL with worsening symptoms and diffuse adenopathy after 1 year of observation receives venetoclax/obinutuzumab and attains a complete response (21:29)CME information and select publications
• 
  Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3 06.09.2026 22мин

  Featuring perspectives from Prof John Seymour, including the following topics:Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)CME information and select publications
• 
  AKT Inhibition in Prostate Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium 05.09.2026 17мин

  Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:Tolerability of capivasertib and management of associated side effects — Question from Neeraj Agarwal, MD, FASCO (0:00)Case: A man in his early 70s with Type 2 diabetes presents with metastatic hormone-sensitive prostate cancer with widespread bone metastases and PTEN deficiency on next-generation sequencing and receives relugolix/darolutamide — Rana R McKay, MD, FASCO (8:39)CME information and select publications
• 
  ER-Positive, HER2-Positive Metastatic Breast Cancer — Patterns of Care Among Community Oncologists 03.09.2026 58мин

  Featuring perspectives from Dr Lisa A Carey and Dr Maha Hussain, including the following topics:Introduction (0:00)HER2 History (1:32)Cases from the GMO Survey (7:06)Biology and Selection of First-Line Therapy for HR-Positive, HER2-Positive Metastatic Breast Cancer (mBC) — Dr Mahtani (19:56)Faculty Case Presentations (31:37)Patterns of Care Survey — Part 1 (38:26)Optimizing the Use of Up-Front Maintenance Therapy for HER2-Positive mBC — Dr Carey (44:53)Faculty Case Presentations (54:13)CME information and select publications
• 
  Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program 02.09.2026 58мин

  Featuring perspectives from Dr William G Wierda, including the following topics:Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)Sequencing Road Map (12:39)Key Datasets — Pirtobrutinib (21:08)Investigator Survey (34:09)Chimeric Antigen Receptor T-Cell Therapy (45:08)Other Novel Therapy Approaches (49:58)EHA 2026 (54:45)CME information and select publications
• 
  Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer — An Interview with Prof Ticiana Leal 01.09.2026 54мин

  Featuring an interview with Prof Ticiana Leal, including the following topics:Pathophysiology and clinical signs and symptoms (0:00)Screening and/or diagnostic approaches (5:45)Potential impact of available therapies for small cell lung cancer (SCLC) on paraneoplastic syndromes (7:36)Key clinical trial data for amifampridine and practicalities of its administration (14:05)Building awareness among patients, caregivers and the oncology community (22:37)Role of pyridostigmine in managing Lambert-Eaton myasthenic syndrome (LEMS); potential integration of EMG (electromyography) into monitoring (25:35)Case: A man in his early 70s who receives a diagnosis of limited-stage SCLC (LS-SCLC) with LEMS and undergoes treatment (27:41)Case: A woman in her late 70s already diagnosed with LS-SCLC who is subsequently evaluated and treated for LEMS (37:55)Current research and potential developments in the treatment of SCLC (48:32)CME information and select publications
• 
  For Oncology Nurses: Prostate Cancer — Proceedings from the 2026 Annual ONS Congress 31.08.2026 1ч 28мин

  Featuring perspectives from Mr Michael Lai, Dr Scott T Tagawa, Ms Stacy E Walker and Dr Evan Y Yu, moderated by Dr Tagawa, including the following topics:Introduction (0:00)Overview of Prostate Cancer (3:00)Hormonal Therapy for Nonmetastatic and Metastatic Hormone-Sensitive Prostate Cancer (HSPC) (6:12)Potential Role of Capivasertib in Metastatic HSPC (27:22)Current and Potential Future Role of PARP Inhibitors in Metastatic PC (46:39)Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic PC (1:09:14)CME information and select publications
• 
  Metastatic Triple-Negative Breast Cancer — Patterns of Care 28.08.2026 1ч 2мин

  Featuring perspectives from Prof Peter Schmid and Dr Melinda Telli, including the following topics:Introduction: TROP2-Targeting Antibody-Drug Conjugates (ADCs) for Metastatic Triple-Negative Breast Cancer (0:00)First-Line Therapy (PD-L1 Negative) (6:53)First-Line Therapy (PD-L1 Positive) (23:40)Second-Line Therapy (Sequencing) (34:08)Adverse Events with TROP2-Targeting ADCs (43:43)CME information and select publications
• 
  Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 4: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium 27.08.2026 15мин

  Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A patient with T4 disease, pelvic wall involvement and a positive pelvic node treated as metastatic disease with enfortumab vedotin and pembrolizumab attains a complete response on imaging after 6 cycles (0:00)Case: A man with muscle-invasive bladder cancer who receives neoadjuvant chemotherapy with durvalumab receives positive circulating tumor DNA results before cystectomy and negative results after surgery (7:41)CME information and select publications
• 
  Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GU Cancers Symposium 26.08.2026 20мин

  Featuring perspectives from Dr Terence Friedlander, Dr Matthew Galsky, Dr Shilpa Gupta and Prof Andrea Necchi, moderated by Dr Friedlander, including the following topics:Case: A man in his early 80s with non-muscle-invasive bladder cancer (NMIBC) monitored by repeat TURBTs develops localized muscle-invasive bladder cancer and enrolls in a clinical trial of neoadjuvant enfortumab vedotin with pembrolizumab (0:00)Case: A man in his late 70s with newly diagnosed NMIBC with carcinoma in situ (CIS) receives BCG induction and experiences relapse of CIS during BCG maintenance (9:24)CME information and select publications
• 
  Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances 25.08.2026 1ч

  Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)CME information and select publications